Abstract
Renal cell cancer is fastly growing in incidence worldwide. No adjuvant therapy has been unarguably proven feasible so far, although an autologous vaccine has achieved a significant benefit. An effective agent in adjuvant therapy against renal cell cancer must achieve several goals. It should be relatively non toxic, have estabilished efficacy in the metastatic setting, and have demonstrated efficacy against the standard of care in randomized phase III trials. The development of adjuvant therapy requires the properly identification of patients at highest risk of relapse, as potential benefactors of adjuvant therapy development. Our ability to predict when and where patients will recur has much room for improvement. Therefore several models and nomograms including the most important prognostic and predictive factors have been developed. Nevertheless, during the past few years, major advances have been made concerning the metastatic setting of the disease with the arrival of new drug classes such as tyrosine kinase inhibitors and monoclonal antibodies, strongly improving overall and progression free survivals, renewing hopes on activity regarding the adjuvant therapy. Several trials are today in progress to evaluate the effectiveness of antiangiogenic agents in this area. An overall review of the completed and upcoming trials and patents shall be discussed here.
Keywords: Renal cell cancer, adjuvant therapy, immunotherapy, vaccine, new drugs
Recent Patents on Anti-Cancer Drug Discovery
Title: Renal Cell Cancer: State of the Art in Adjuvant Therapy
Volume: 5 Issue: 3
Author(s): Sebastiano Buti and Rodrigo Kraft Rovere
Affiliation:
Keywords: Renal cell cancer, adjuvant therapy, immunotherapy, vaccine, new drugs
Abstract: Renal cell cancer is fastly growing in incidence worldwide. No adjuvant therapy has been unarguably proven feasible so far, although an autologous vaccine has achieved a significant benefit. An effective agent in adjuvant therapy against renal cell cancer must achieve several goals. It should be relatively non toxic, have estabilished efficacy in the metastatic setting, and have demonstrated efficacy against the standard of care in randomized phase III trials. The development of adjuvant therapy requires the properly identification of patients at highest risk of relapse, as potential benefactors of adjuvant therapy development. Our ability to predict when and where patients will recur has much room for improvement. Therefore several models and nomograms including the most important prognostic and predictive factors have been developed. Nevertheless, during the past few years, major advances have been made concerning the metastatic setting of the disease with the arrival of new drug classes such as tyrosine kinase inhibitors and monoclonal antibodies, strongly improving overall and progression free survivals, renewing hopes on activity regarding the adjuvant therapy. Several trials are today in progress to evaluate the effectiveness of antiangiogenic agents in this area. An overall review of the completed and upcoming trials and patents shall be discussed here.
Export Options
About this article
Cite this article as:
Buti Sebastiano and Kraft Rovere Rodrigo, Renal Cell Cancer: State of the Art in Adjuvant Therapy, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (3) . https://dx.doi.org/10.2174/157489210791760544
DOI https://dx.doi.org/10.2174/157489210791760544 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Role of Drug Metabolism and its Mediated DDI in Drug Efficacy and Safety Part 2)
Current Drug Metabolism Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism A Sensitive Determination of Ammonia and Nitrite in Exhaled Breath Condensate of Healthy Humans by Using Berthelot Reaction
Current Pharmaceutical Analysis Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Editorial [Hot Topic: Development of Drugs Interfering with Apoptosis (Executive Guest Editor: Sebastiano Cavallaro)]
Current Pharmaceutical Design Editorial (Thematic Issue: Polymers in Drug Delivery)
Current Pharmaceutical Design Bisphosphonate Osteonecrosis (BON): Unanswered Questions and Research Possibilities
Reviews on Recent Clinical Trials Regulation and Function of Antimicrobial Peptides in Immunity and Diseases of the Lung
Protein & Peptide Letters Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Mechanisms of Cellular Resistance to Camptothecins
Current Medicinal Chemistry DSPE-PEG: A Distinctive Component in Drug Delivery System
Current Pharmaceutical Design Selective Toxicity of Apigenin on Cancerous Hepatocytes by Directly Targeting their Mitochondria
Anti-Cancer Agents in Medicinal Chemistry A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets The Comparison of Pleural Fluid TNF-α and IL-10 Levels with ADA in Tuberculous Pleural Effusion
Current Medicinal Chemistry CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets HER-2 / neu and Topoisomerase IIα - Simultaneous Drug Targets in Cancer
Combinatorial Chemistry & High Throughput Screening Pharmacophore Modeling for Antitargets
Current Topics in Medicinal Chemistry